In our current study, the IDH1 wild type A172 GBM line (expressing TP53 and EGFR and bearing mutations in PTEN and CDKN2A/p16INK4a) [42, 43] and U87MG (expressing TP53 with PTEN mutations, CDKN2C/p18INK4C mutations, and O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation) [42, 44] are employed as models akin to the AC-like and MES-like subtypes, respectively. The gene discussed is CDKN2A; the disease is glioblastoma.